27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
The US Food and Drug Administration (FDA) on Friday approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. 28 September 2024
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Repair Biotechnologies, a company developing therapies to reverse atherosclerotic plaque, has entered into a collaboration with Genevant Sciences, a specialist in nucleic acid delivery technology. 27 September 2024
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
Kees Melief, chief scientific officer of ISA Pharmaceuticals, provides an Expert View on why therapeutic cancer vaccines will be a success following many years of being out of favor. 3 September 2021
Shares in Forte Biosciences plummeted 81.6% to $5.25 pre-market today, after it revealed late Thursday that top-line data from its Phase II clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance. 3 September 2021
Shares of Swedish Orphan Biovitrum, also known as Sobi, jumped as much as 23.6% to 235 Swedish kronor early today, after the company revealed it has received a takeover bid. 3 September 2021
Ultomiris (ravulizumab) has now been approved in the European Union for expanded use to include children (with a body weight of 10 kg or above) and adolescents with paroxysmal nocturnal hemoglobinuria (PNH). 3 September 2021
Portugal’s largest drugmaker BIAL has agreed with Sunovion Pharmaceuticals to buy the rights to commercialize apomorphine sublingual film in the European Union (EU), the European Economic Area (EEA) and the UK. 2 September 2021
Swedish biotech pairing Alligator Bioscience and Scandion Oncology have concluded a research collaboration, describing its outcome as positive. 2 September 2021
A US Food and Drug Administration (FDA) review of a large clinical trial has led the agency to conclude that JAK inhibitors lead to an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death. 2 September 2021
Ardena, a Belgian pharmaceutical ctract development and manufacturing Organization (CDMO), says it has acquired Idifarma, a Spain-based contract manufacturer of niche and highly potent generic and innovative drugs. 2 September 2021
Precision BioSciences and UK biotech Tiziana Life Sciences have entered an exclusive license agreement to explore Tiziana's foralumab, a fully human anti-CD3 monoclonal antibody (MAb), as an agent to induce tolerance of allogeneic CAR T-cells to potentially improve the clinical outcome of CAR-T cell therapy. 2 September 2021
Japan’s largest drugmaker Takeda Pharmaceutical today revealed that the Phase III PANTHER (Pevonedistat-3001) study did not achieve pre-defined statistical significance for the primary endpoint of event-free survival (EFS). 2 September 2021
Brukinsa (zanubrutinib) has received approval from the US Food and Drug Administration (FDA) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). 2 September 2021
The US Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic Invega Hafyera (six-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. 2 September 2021
Research from industry analyst GlobalData underscores the dominance of two players in the cystic fibrosis (CF) space - Vertex Pharmaceuticals and AbbVie. 2 September 2021
Another coronavirus vaccine is moving towards the finishing line, as South Korean firm SK Bioscience announced the initiation of Phase III tests for its candidate, GBP510. 1 September 2021
GlaxoSmithKline has launched its shingles vaccine, Shingrix (zoster vaccine recombinant), in the UK. The vaccine will be available to purchase from pharmacies and private healthcare practices, as well as through a national immunization program for people in their seventies. 1 September 2021
Merck & Co has announced a label update for Keytruda (pembrolizumab), the US pharma giant’s blockbuster anti-PD-1 therapy, for its indication in first-line advanced urothelial carcinoma (bladder cancer) in the USA. 1 September 2021
All signs point to an M&A boom in late 2021 and throughout 2022. In this episode, Lance Minor, principal and national co-leader of the life sciences practice at BDO, provides valuable insight into current and emerging trends in the biotech investing landscape. 1 September 2021